AstraZeneca, Dako Team on Companion Dx | GenomeWeb

NEW YORK (GenomeWeb News) – AstraZeneca and Dako Denmark announced today that they will collaborate on developing companion diagnostics for multiple AstraZeneca oncology drug programs.

The firms said that the AstraZeneca drug candidates will be biologics and small molecule drugs that are in various stages of development. They did not name specific cancer targets, nor did they provide any financial details of the agreement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: peanut subgenome progenitor sequence, homozygosity mapping and linkage analyses using exome data, and more.

Tech companies like Microsoft are looking into DNA as a data storage device, Scientific American writes.

The New York Times writes that the Max Planck Institute for Infection Biology's Emmanuelle Charpentier has always been on the move, though now it's more about CRISPR.

The European Union calls for all publicly funded scientific papers to be immediately freely accessible to the public by 2020.